{
    "id": 8571,
    "fullName": "HGF amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HGF amp indicates an increased number of copies of the HGF gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3082,
        "geneSymbol": "HGF",
        "terms": [
            "HGF",
            "DFNB39",
            "F-TCF",
            "HGFB",
            "HPTA",
            "SF"
        ]
    },
    "variant": "amp",
    "createDate": "07/02/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11442,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with HGF amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",
            "molecularProfile": {
                "id": 8467,
                "profileName": "HGF amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9389,
                    "pubMedId": 28644771,
                    "title": "Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28644771"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6096,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of EML4-ALK positive human non-small cell lung carcinoma cell lines that acquired Alecensa (alectinib)-resistance through amplification of HGF in culture and in xenograft models (PMID: 26719536).",
            "molecularProfile": {
                "id": 22704,
                "profileName": "EML4 - ALK HGF amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5313,
                    "pubMedId": 26719536,
                    "title": "Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719536"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6094,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prolonged exposure to Alecensa (alectinib) resulted in acquired resistance through amplification of HGF in a non-small cell lung carcinoma cell line originally harboring EML4-ALK in culture (PMID: 26719536).",
            "molecularProfile": {
                "id": 22704,
                "profileName": "EML4 - ALK HGF amp"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5313,
                    "pubMedId": 26719536,
                    "title": "Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719536"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8467,
            "profileName": "HGF amp",
            "profileTreatmentApproaches": [
                {
                    "id": 5910,
                    "name": "MET Inhibitor",
                    "profileName": "HGF amp"
                },
                {
                    "id": 14010,
                    "name": "HGF Antibody",
                    "profileName": "HGF amp"
                },
                {
                    "id": 5911,
                    "name": "MET Antibody",
                    "profileName": "HGF amp"
                }
            ]
        },
        {
            "id": 22704,
            "profileName": "EML4 - ALK HGF amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}